OPR - Delayed Quote • USD AZN Apr 2024 72.000 call (AZN240426C00072000) Follow 3.4200 +0.1800 (+5.56%) At close: April 26 at 3:01 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for AZN240426C00072000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: AZN Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain' AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript AstraZeneca reinforcing supply chain amid global tensions: CEO 20 Fastest Growing Health Tech Companies in the World Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
